Overview

MBG453 in Lower Risk MDS

Status:
Not yet recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

This research study is assessing the efficacy of MBG-453, a humanized monoclonal antibody, in treating myelodysplastic syndromes (MDS). The name of the study drug involved in this study is MBG453.

Phase:

Phase 2

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborator:

Novartis